FRANKFURT (dpa-AFX) - The imminent decision on the approval of cannabis in Germany caused relevant sector stocks to jump further on Friday. This was particularly true for Synbiotic shares, which have been experiencing a price rally for days.

On Friday, they shot up by a third to 15 euros and even peaked at 19.50 euros. Since mid-January, their price has risen around fivefold. Cantourage shares have also benefited recently, but the company is more strongly positioned than Synbiotic in the field of medical cannabis applications.

Investors remain euphoric that the Bundestag will decide on the legalization of cannabis in Germany this Friday. The legislative plans of the traffic light coalition envisage a controlled release with numerous rules and regulations. Cultivation and possession of certain quantities for personal consumption would be permitted for adults from April 1. Clubs for non-commercial cultivation are to become possible on July 1. There has been widespread criticism of the plans, including from medical associations, the judiciary and domestic politicians at federal and state level./tih/jha/